PMID- 35177359
OWN - NLM
STAT- MEDLINE
DCOM- 20231222
LR  - 20231222
IS  - 1878-4046 (Electronic)
IS  - 1076-6332 (Linking)
VI  - 29
IP  - 11
DP  - 2022 Nov
TI  - The Efficacy of Drug-eluting Bead Transarterial Chemoembolization Loaded With 
      Oxaliplatin for the Treatment of Stage III-IV Non-small-cell Lung Cancer.
PG  - 1641-1646
LID - S1076-6332(22)00065-4 [pii]
LID - 10.1016/j.acra.2022.01.015 [doi]
AB  - RATIONALE AND OBJECTIVES: To explore the safety and efficacy of drug-eluting bead 
      transarterial chemoembolization (DEB-TACE) loaded with oxaliplatin for stage 
      III-IV non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: From October 
      2018 to May 2021, a total of 31 patients with stage III-IV NSCLC received 
      DEB-TACE loaded with oxaliplatin. Demographic characteristics, adverse events 
      (AEs), and treatment responses were collected. Overall survival (OS) and 
      progression-free survival (PFS) were calculated using the Kaplan-Meier method. 
      RESULTS: All 31 patients successfully received DEB-TACE loaded with oxaliplatin. 
      No procedure-related severe adverse events occurred. Hemoptysis symptoms 
      presented in 8 patients but disappeared within 1-3 days. After DEB-TACE for 1, 2, 
      and 6 months, the objective response rate (ORR) was 42%, 35%, and 26%, while the 
      disease control rate (DCR) was 90%, 84% and 61%, respectively. The median PFS was 
      7 months (range 1-31 months), and the PFS rates at 3, 6, and 12 months were 87%, 
      71% and 29%, respectively. The median OS was 11 months (range 1-31 months), with 
      OS rates of 87%, 77%, and 39% at 3, 6, and 12 months, respectively. CONCLUSION: 
      Oxaliplatin-loaded DEB-TACE is a feasible, safe, and effective treatment for 
      patients with advanced refractory non-small-cell lung cancer.
CI  - Copyright (c) 2022 The Association of University Radiologists. Published by 
      Elsevier Inc. All rights reserved.
FAU - Ren, Kewei
AU  - Ren K
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Wang, Jianan
AU  - Wang J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Li, Yahua
AU  - Li Y
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Li, Zongming
AU  - Li Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Wu, Kunpeng
AU  - Wu K
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Zhou, Zihe
AU  - Zhou Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Li, Yifan
AU  - Li Y
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University.
FAU - Han, Xinwei
AU  - Han X
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University. Electronic address: fcchanxw@zzu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220215
PL  - United States
TA  - Acad Radiol
JT  - Academic radiology
JID - 9440159
RN  - 04ZR38536J (Oxaliplatin)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/therapy
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Liver Neoplasms/therapy
MH  - Oxaliplatin
MH  - *Chemoembolization, Therapeutic
MH  - *Lung Neoplasms/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Non-small-cell lung cancer
OT  - drug-eluting bead transarterial chemoembolization (DEB-TACE)
OT  - oxaliplatin
EDAT- 2022/02/19 06:00
MHDA- 2023/12/22 06:43
CRDT- 2022/02/18 05:36
PHST- 2021/11/28 00:00 [received]
PHST- 2022/01/17 00:00 [revised]
PHST- 2022/01/18 00:00 [accepted]
PHST- 2023/12/22 06:43 [medline]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/02/18 05:36 [entrez]
AID - S1076-6332(22)00065-4 [pii]
AID - 10.1016/j.acra.2022.01.015 [doi]
PST - ppublish
SO  - Acad Radiol. 2022 Nov;29(11):1641-1646. doi: 10.1016/j.acra.2022.01.015. Epub 
      2022 Feb 15.